CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,083,813 | -38.7% | 324,499 | -10.8% | 0.00% | -50.0% |
| Q2 2023 | $11,562,150 | +25.7% | 363,704 | -3.5% | 0.00% | 0.0% |
| Q1 2023 | $9,196,421 | -5.0% | 377,057 | +22.8% | 0.00% | 0.0% |
| Q4 2022 | $9,681,203 | +39.4% | 306,950 | +24.9% | 0.00% | 0.0% |
| Q3 2022 | $6,946,000 | +159.9% | 245,797 | +143.1% | 0.00% | +100.0% |
| Q2 2022 | $2,673,000 | -7.2% | 101,104 | +22.9% | 0.00% | 0.0% |
| Q1 2022 | $2,880,000 | -78.9% | 82,265 | -80.5% | 0.00% | -66.7% |
| Q4 2021 | $13,671,000 | -9.1% | 421,688 | -17.3% | 0.00% | 0.0% |
| Q3 2021 | $15,038,000 | +475.7% | 509,747 | +167.9% | 0.00% | +200.0% |
| Q1 2021 | $2,612,000 | +456.9% | 190,266 | +572.1% | 0.00% | – |
| Q4 2020 | $469,000 | – | 28,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |